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ABSTRACT
This study is an effort to develop a tool for early detection of pancreatic cancer using
evidential reasoning. An evidential reasoning model predicts the likelihood of an
individual developing pancreatic cancer by processing the outputs of a Support
Vector Classifier, and other input factors such as smoking history, drinking history,
sequencing reads, biopsy location, family and personal health history. Certain
features of the genomic data along with the mutated gene sequence of pancreatic
cancer patients was obtained from the National Cancer Institute (NIH) Genomic
Data Commons (GDC). This data was used to train the SVC. A prediction accuracy
of ~85% with a ROC AUC of 83.4% was achieved. Synthetic data was assembled
in different combinations to evaluate the working of evidential reasoning model.
Using this, variations in the belief interval of developing pancreatic cancer are
observed. When the model is provided with an input of high smoking history and
family history of cancer, an increase in the evidential reasoning interval in belief of
pancreatic cancer and support in the machine learning model prediction is observed.
Likewise, decrease in the quantity of genetic material and an irregularity in the
cellular structure near the pancreas increases support in the machine learning
classifier’s prediction of having pancreatic cancer. This evidence-based approach is
an attempt to diagnose the pancreatic cancer at a premalignant stage. Future work
includes using the real sequencing reads as well as accurate habits and real medical
and family history of individuals to increase the efficiency of the evidential
reasoning model. Next steps also involve trying out different machine learning
models to observe their performance on the dataset considered in this study.

Key Words: Pancreatic Cancer, Evidential Reasoning, Next Generation Sequencing,
Genetic Mutations, Machine Learning, Support Vector Classifier, Biomarkers.
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INTRODUCTION
Pancreatic cancer is belligerent in its own way, since it hardly displays any
observable symptoms before metastasis. Due to this, it is difficult to treat it before it
spreads beyond control. The lone remedial option is the surgical resection of the
tumor (Amin & DiMaio, 2016). The fact that it is fourth in position to cause cancer
associated deaths reflects the lethality of this disease (Amin & DiMaio, 2016).
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the most aggressive types of
pancreatic cancer in which cancerous tumors develop in the ductal cells of the
pancreas. Tumors are accountable to certain genetic mutations occurring in the cells
nearing pancreas. Several other factors such as smoking and drinking habits, a
history of cancer in the family, and other hereditary factors may lead to aberrant
mutation of these cells (See Appendix A for more information on these factors).
PDAC is not only the most common pancreatic cancer, but also the deadliest one.
The rate of a patient surviving beyond 5 years after being diagnosed with PDAC is
as low as 7% (Gharibi, et al., 2017). This is because the PDAC is very difficult to
detect at an early stage.
The statistics of the pancreatic cancer cases resulting in death is brutal with an
estimate of 83% cases leading to death. (Siegel, Miller, & Jemal, 2015). Gender
wise, pancreatic cancer is observed to be a little more prevalent in males than in
females: 13.9 out of 100,000 for males and 10.9 per 100,000 for females. Ethnicity
wise, African Americans are at a higher risk of developing pancreatic cancer with
probability of almost 15.8 out of 100,000 than that of Asian Americans which is 9.8
out of 100,000 (Howlader, et al., 2016). More age may mean greater likelihood of
developing pancreatic cancer. About 27% of new diagnoses belong to the age group
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of 75 and 84 and 9% are in the age group of 45 and 54 years old (Howlader, et al.,
2016).
PDAC is usually diagnosed at an advanced stage when the tumor has spread beyond
the pancreatic region of the patient. At this point, it is hard to remove the tumor
through surgery (Amin & DiMaio, 2016). As per the study by Gharibi, Adamian,
and Kelber, due to its aggressive nature, PDAC metastasizes rapidly and the
treatment of PDAC becomes extremely challenging (Gharibi, Adamian, & Kelber,
2016). The 5-year survival rate decreases rapidly when PDAC is detected at an
advanced stage. Therefore, there is a need to detect the pancreatic cancer at a
primitive stage when it is localized to pancreas in order to treat it successfully (Amin
& DiMaio, 2016).
The limitation with existing methods to detect PDAC are that they fail in detecting
the disease at a premalignant stage. Since pancreatic cancer causes genetic
alterations, monitoring the presence of biomarkers in a tumor specimen remains a
popular technique. But the attempts made to detect the presence of pre-malignant
tumors by observing the genetic mutations in the patient’s tissue focus on limited
genetic material. Research has found that there are about 63 different genes that get
altered by pancreatic cancer (Gharibi, et al., 2017). Each of these genes may undergo
multiple kinds of mutations, but an effective technique to predict the likelihood of
pancreatic cancer by considering all genetic alterations as well as other factors such
as smoking and drinking history, medical history, cellular structure, and others does
not exist. Hence, there is a need to develop a technique that will predict the likelihood
of a person developing pancreatic cancer at an early stage using various mentioned
factors which may impact the development of pancreatic tumor to ensure timely
treatment.
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BACKGROUND
Limitations of the existing methods in detecting pancreatic cancer at an early stage
exist because of lack of symptoms. Pain in abdomen, jaundice, loss of weight are
common early symptoms of pancreatic cancer. Some of the other symptoms are back
pain, anorexia, heartburn, and dysgeusia (Risch, Yu, Lu, & Kidd, 2005). It is often
the case that symptoms of pancreatic cancer can be confused at later stages with
other ailments. Medical imaging is used to detect the presence of pancreatic cancer
which results in discovery of masses. The noticeable masses are generally detected
at a later stage. At this point, the survival rate of pancreatic cancer drastically
decreases. Thus, lack of imaging technology to detect pancreatic cancer at a
premalignant stage calls for the need to find newer methods which may aid in earlier
detection of this disease. (See Appendix B for imaging technology details)

Use of Biomarkers in Detection
Presence of biomarkers is one of the important techniques in early detection of
pancreatic cancer. Biomarkers are characterized by high presence of cellular
molecules such as proteins, antigens, etc. in pancreatic cancer patients. They can be
found using tissue biopsy of liquid biopsy (Qi, et al., 2018). Samples collected for
studying biomarkers before the diagnosis are very less, but they are the ones which
are preferred over the samples of patients already diagnosed with pancreatic cancer
(O'Brien, et al., 2015).
Carbohydrate antigen 19-9 (CA19-9) is one of the most common biomarkers used
presently, with a sensitivity between 69% - 98% and a specificity between 46% 98%. O’Brien et al. observed that there was a detectable surge in CA19-9 levels 3
2

years prior to PDAC diagnosis (O'Brien, et al., 2015). However, CA19-9 is not
specifically related to pancreatic cancer as it is also detected in gastrointestinal
tumors and hence cannot be sufficient enough to be considered alone as a biomarker
in identification of pancreatic cancer.

Existing Research in Genomic Biomarkers
There has been a significant body of research in detection of pancreatic cancercausing cell mutations. Various literature sources study the presence of specific
biomarkers which may lead to pancreatic cancer and there is a considerable
development in this research suggesting the presence of certain genetic material or
biomarkers in the tissue specimen of patients is indicative of presence of malignant
tumors in their pancreas. Experiments help to identify characteristics of these
biomarkers and how they can potentially cause PDAC. Traditional biomarker
detection techniques use tissue biopsy method to detect the presence of malignant
tumors. This involves sectioning the patient’s tissue using surgical or needle biopsy
(Qi, et al., 2018). In contrast to the invasive traditional biopsy techniques, Z. Qi et
al. suggest that inference based on presence of a single biomarker, or study of a
single biopsy sample may provide only limited information as the tumors and their
genetic composition is found to be heterogenic. They argue that due to the limited
true positive and true negative rates provided by biomarkers such as
carcinoembryonic antigen (CEA) and carbohydrate antigen, there is a need for a
better technique that can monitor new biomarkers. This study further suggests that
liquid biopsy is a promising technique because of its non-invasiveness and
effectiveness in detecting circulating tumor cells (CTCs) and cell-free circulating
nucleic acids (cfNAs) which keep circulating in the body fluids such as blood.
2

However, one of the major limitations associated with liquid biopsy technique is that
it relies more on body fluids rather than cancerous tumors to detect the biomarkers,
which may produce misleading conclusions (Qi, et al., 2018).
A. Gharibi et al. study the presence of other biomarkers which may indicate the
presence of ductal tumors. They analyzed and found that integrin alpha 1 (ITGA1),
acts as an ideal biomarker for diagnosis and therapeutic technique for PDAC.
Presence of ITGA 1 is detected in high quantity in 42% of the tumor tissue of PDAC
patients, whereas it does not occur in the normal pancreatic ductal epithelial cells
(Gharibi, et al., 2017). Thus, it can be used effectively in the PDAC detection.
In another study, A. Gharibi, Y. Adamian, and J.A. Kelber examine various genetic
mutations and suggest that Kirsten rat sarcoma (KRas) is the most frequently
observed gene that is mutated in PDAC related cases (Gharibi, Adamian, & Kelber,
2016). It is followed by other genes including p53, p16, SMAD4, PUC1, and SRC.
These genetic materials after undergoing mutations, lead to inappropriate
proliferation of cells in pancreas. Amongst these, p53, p16, and SMAD4 are tumor
suppressing transcription factors, which normally arrest the progression of cell
cycle; however, their mutated presence in abnormal quantities or their absence, leads
to cell proliferation (Gharibi, Adamian, & Kelber, 2016). Hence, these are some of
the important biomarkers in PDAC treatment.
Similarly, J. A. Kelber et al. found that Pseudopodium-Enriched Atypical Kinase
One (PEAK1) helps in regulation of cell migration and proliferation. It is a
biomarker with therapeutic target in PDAC, which regulates the necessary cell
migration characteristics such as shape change of cells (Kelber, et al., 2012). Thus,
this research paper concludes that PEAK1 plays a major role in limiting cancer cell
migration as well as growth.
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However, one major limitation of these studies is that they consider only a few
genetic material or biomarkers which might prove unreliable given that the tumors
may contain a variety of genetic mutations, but the biomarkers under consideration
are limited. Moreover, it is observed that barring some genes, not all the biomarkers
can aid in detecting of pancreatic cancer early.

Circulating Tumor Cells
Circulating Tumor Cells (CTCs) are the tumor shed cells which circulate in the blood
stream of the cancer patients. A study found out that out of 12 pancreatic cancer
subjects under consideration, 11 had KRAS gene mutations in their CTCs (Court, et
al., 2016). Court et al. concluded that at least 10 CTCs should be present in order to
detect KRAS mutations. Moreover, 7.5 mL of blood sample contains only about 150 CTCs along with more than a million white blood cells. Hence to detect CTCs in
blood sample, a test with a high sensitivity and specificity is needed because of lesser
number of CTCs in bloodstream (Court, et al., 2016). CTCs are believed to be a good
prognostic biomarker, but out of all the CTCs detaching from tumors, only 0.01%
develop into metastases. Newer techniques are being formulated to detect CTCs as
they are great potential biomarkers in cancer development.

Sequencing
Classification of gene mutations is achieved using various sequencing technologies.
Study by Lawrence, et al., mentions methods such as Mutation Significance of
Covariance (MutSigCV) which are widely used to classify gene mutations from the
tumor tissue of an affected individual. Lawrence et al. used MutSigCV to discover
2

abnormal variation in mutation frequency and spectrum observed in tumors for
different cancer types by applying the technique on exome sequences from 3,083
tumor–normal pairs. Cancer related genes or mutations truly found in cancerous
tumors are found out by MutSigCV by introducing the analysis with mutational
heterogeneity. (Lawrence, et al., 2013). Using this sequencing approach, genes such
as KRas, TP53, CDKN2A, Smad4, BCLAF1, IRF6, FLG, AXIN1, GLI3 and
PIK3CA were found to be mutated expressively. Pancreatic tumor cells were
separated by microdissection approach from the microenvironment in 109 affected
patients using surgical resection. Various other sequencing techniques also aided in
discovering novel mutations in these tumorous cells which underwent whole-exome
sequencing technique (Witkiewicz, et al., 2015) (See Appendix C for more details
on sequencing details).

Machine Learning
Machine learning has proved to be a promising technique to detect pancreatic
cancer-causing genetic mutations. In an interesting study, G. P. Way et al. developed
a machine learning model to detect abnormal Ras activation in the cancer tumors
using the knowledge of Kirsten Rat Sarcoma (KRAS), Neuroblastoma Rat Sarcoma
(NRAS) and KRAS, also known as transforming protein p21. The mutations in Ras
pathway genes are known to drive PDAC. A classification model was developed for
distinguishing the aberrant Ras pathway activity in tumors using features such as
RNA-seq, copy number, and mutation data. A logistic regression classifier is used
to train a model by combining these features from 33 types of cancers from The
Cancer Genome Atlas (TCGA) PanCanAtlas database. The model learned a
combination of weights and gene related important scores that separate aberrant
patterns (Way G. P., et al., 2018). The results of this classification model by the
2

authors were observed in terms of area above 84% covered by the receiver operating
characteristic (AUROC) curve and above 63% covered by the precision recall
(AUPR) curve (Way G. P., et al., 2018).
In other research, J. Jeon et al., considered mutated genetic data as the dataset from
the Catalogue of Somatic Mutations in Cancer (COSMIC) database. In general
terms, they computed the probability of 15,663 proteins of being an appropriate drug
target in case of treatment of cancers such as pancreatic cancer, breast cancer, and
ovarian cancer. Using features such as mRNA expression intensity score, gene
essentiality score, DNA copy number and mutation occurrence, 3 classifiers were
developed with the help of support vector machine (SVM) and RBF kernel. SVM
perform exceptionally well in inferring gene-disease correlation and in identifying
the drugs with the target disease (Jeon, et al., 2014). It was further found that of the
three diseases they considered the SVM could predict 43 of the 69 drug targets
considered. Out of all the three classifiers, the combined accuracy obtained was
91.69%, meanwhile the specificity was 91.91%. A major drawback of this study is
that these features provide little throughput screening and relatively low coverage of
human genomic data which confines their use in generalized identification of
genome-wide drug targets (Jeon, et al., 2014)
Thus, using machine learning in pancreatic cancer detection is a novel technique that
can aid in early diagnosis of the disease. It can also create a breakthrough in the early
treatment of this disease which is the goal. But it still has a scope for improvement
as currently, only limited genomic data has been considered presently.

Existing Research in Evidence Based Approach
The work done by Sharghi which has been extended in this study is based on a
similar evidential reasoning approach (Sharghi, 2019). This dataset gathered for this
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study consisted of mutations from the Cancer Genome Atlas – Pancreatic
Adenocarcinoma (TCGA-PAAD) project. Sharghi used these mutations to find the
cases from other cancer projects that shared the mutations from TCGA-PAAD
project (Sharghi, 2019). A permutation factor was made use of, to find the mutation
entries for every individual case. This dataset had an imbalance of classification
labels as only a certain percent of data was queried for each case. The Support
Vector Classifier was trained on the dataset of unique gene mutation permutation
and its pancreatic cancer label. An average precision score of 92% was obtained
along with a ROC AUC of 92%. As per Sharghi, even though the results of the
classifier were promising, its performance was still questionable owing to the limited
size of 185 cases. Sharghi expressed a need for utilizing a larger dataset to find more
common gene mutation combinations (Sharghi, 2019). The present study tries to
overcome this limitation by considering a larger volume of dataset with mutations
observed in every project in the GDC portal along with additional features such as
impact of the variant on protein and the project in which the mutation occurred.
Further, various experiments were carried out considering different scenarios
regarding the smoking and drinking history of individual, family and personal
history along with the machine learning prediction, biopsy site, and even the
sequencing reads and NGS technologies. These scenarios were input to an evidential
reasoning model which produced promising results.

Addressing the Technological Gaps
The present diagnostic methods fail to detect pancreatic cancer in the early stage
resulting in lowering the rate of survival of this disease. According to Gharibi et al.,
pancreatic cancer starts metastasis 10 years prior to showing symptoms in the body
of the patient (Gharibi, et al., 2017). Thus, if the mutations in the genes leading to
2

pancreatic cancer are detected early, the cancer can be removed effectively before it
spreads beyond the pancreas, after which it becomes very difficult to treat the
disease.
Further, diagnosing a lethal disease like pancreatic cancer using a few biomarkers or
analyzing limited genomic data using machine learning may prove unreliable and
inaccurate. The reason behind this being that there are many factors responsible for
causing the aberrant mutation of cells in the pancreatic tissues. These factors may be
environmental (tobacco intake, alcohol consumption, etc.) or even hereditary
(genetic mutations occurring due to inherited conditions) (See Appendix A for more
details regarding the causes of pancreatic cancer). All these factors including the
statistical data could be vague, inaccurate, diverse, imprecise, or even insufficient to
certain extent. Moreover, if age and ethnicity wise data of people at higher risk is
considered, there is a chance that only a subset of a wider population being diagnosed
eventually (Sharghi, 2019).
The Belief Function (BF) and evidential reason calculi is a part of a sophisticated
mathematical approach used to formulate reasonable and precise results regarding
likelihood of developing pancreatic cancer. It does this in a more flexible and less
restrictive manner than the traditional statistical and probabilistic approaches
(Lowrance, et al., 1991).
A useful knowledge source can be developed using imperfect and diverse
information such as the genomic structure, alcohol consumption habits, smoking
habits, health history, biopsy location, etc. This tactic can aid in early cancer
diagnosis if supplied with real time data, by using belief functions and evidencebased reasoning approach. The work described in this report attempts analyzing the
feasibility of an evidence-based approach to represent reasonable information from
complex and miscellaneous dataset.
2

APPROACH AND METHOD
Even though machine learning approach is establishing a hold in the diagnosis
world, presently, there are no techniques that could consider a plethora of significant
factors such as medical and personal history, smoking or drinking history by
screening the patient and estimate the likelihood of developing the pancreatic cancer
before its metastasis (Sharghi, 2019). Data analysis techniques depend on limited
genomic data supplied to machine learning classifiers predicting an outcome. This
can be exemplified in the study by Way et al. where a machine learning classifier
detected altered Ras activity with promising results, but the data considered was
limited to genomic evidence and transcriptome (Way G. P., et al., 2018). To
overcome these shortcomings, a sophisticated and powerful mathematical calculus
is needed to represent, combine, and draw inferences from such types of data and
information. With the aid of available genetic material such as the mutations
undergone by the genes, and other factors affecting the likelihood of developing
pancreatic cancer, a screening option could be developed to detect whether an
individual stands a greater risk of suffering from this cancer.
Multiple environmental and hereditary factors affect the pancreatic cancer detection.
Evidential Reasoning (ER) approach draws information from these diverse factors
and helps combine it to produce the likelihood of developing pancreatic cancer.
Machine learning model is one of the diverse yet useful sources which analyzes
genetic data to predict if a subject has developed pancreatic cancer or not. The
machine learning (ML) classifier is based purely on analysis of genomic data, it lacks
considering the impact of other factors responsible for genetic alterations such as the
medical history or smoking and alcohol habits. Evidential reasoning allows us to
incorporate all these factors along with the ML prediction, without knowing its
2

distribution even though some of the data may be imprecise, estimated, and
incomplete. ML prediction is also affected by factors such as the quality of
sequencing reads and the type of technology used to sequence the genomic data.
Moreover, ML prediction is impacted by the amount of genetic material considered
during the biopsy and its site and structure. Even though the ML classifier does not
use these factors as its features, the ER model allows to amalgamate ML prediction
results along with all of these factors and forms a consensus on the prediction of
developing pancreatic cancer.
Heavy tobacco use constitutes around one fourth of cancer related deaths with a 5-6
fold increased risk of developing pancreatic cancer due to smoking a pack of
cigarettes in a day (Pandol, Apte, Wilson, Gukovskaya, & Edderkaoui, 2012), and
an elevated risk of about 1.5 to 6-fold due to drinking alcohol (Gupta, Wang, Holly,
& Bracci, 2010). Thus, evidences of smoking and drinking histories are features that
can be helpful in balancing the results of an otherwise unbiassed machine learning
classifier, towards a higher belief of having pancreatic cancer (Sharghi, 2019).
Moreover, DNA Single Nucleotide Polymorphisms (SNP) comprising of
homopolymer region may lead to sequencing errors negatively affecting the
accuracy of machine learning classifier using the genomic data. Thus, errors
occurring while sequencing genomic data can be considered as another factor for
orienting the machine learning results (Sharghi, 2019). In this way, the evidential
reasoning approach can be used to make a more precise prediction about the
pancreatic cancer diagnosis using mathematical calculus by looking past the
traditional statistical and probabilistic approach (Sharghi, 2019).Thus, rather than
relying on a single source of data, this approach takes into account various factors
which may be diverse and imprecise. Each of these factors are assigned a belief and
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are weighed together to make a final decision which measures the support in favor
of pancreatic cancer prediction as well as no pancreatic cancer prediction.
The approach used in evidential reasoning model considers as input, factors such as
results of a machine learning classifier, patient’s medical history, family history,
drinking and smoking history, the type of NGS technology used to obtain patient’s
genomic data, biopsy site and cell structure, sequencing read, and amount of genetic
material. Every input factor is known as a frame and a collection of such frames is
called a gallery.
Every frame comprises of propositions defining all the possible scenarios. No two
scenarios can be true together at the same time. A probability signifying truth of the
statement is assigned to each of these propositions. A discount value applied to these
frames indicates the reduction of belief impact in that frame. Such a grid of
interconnected propositions ultimately produces a single resulting prediction of
likelihood of pancreatic cancer as shown in the Figure 1. Propositions for a given
frame can either be discrete or continuous in nature. For instance, the frame
‘Drinking History’ may have propositions such as ‘low’, ‘medium’, or ‘high’,
whereas the frame ‘ML Prediction’ may have propositions such as ‘PC’ (pancreatic
cancer) or ‘NOT_PC’ (no pancreatic cancer). All the features (sequencing read,
family medical history, smoking history, etc.) are represented as similar frames and
are input to the evidential reasoning model. A compatibility relation is the subset of
cross product between two frames meaning that it is the joint possibility distribution
of the frames under consideration. The generalization of the compatibility relation
is defined as ‘the multiplication of possibility distributions’ (Yager, Liu, Dempster,
& Shafter, 2008). It is defined for every frame in the evidential model. A new body
of evidence forms as a result of merging of frames into one another as per
Dempster’s Rule of Combination evidence (Yager, Liu, Dempster, & Shafter, 2008).
2

The propositions in this project are synthesized using NIH GDC dataset (see
Appendix F for more evidential reasoning details).

Figure 1. Evidential Reasoning Model

A machine learning model was developed to determine the classification whether a
subject has or does not have pancreatic cancer. The results of the classification
obtained from the developed machine learning model is one of the frames which are
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provided to the evidential reasoning model. (For more information on how the
classifier was built, please refer Appendix E)

2

EXPERIMENTAL METHOD
This study in this project uses the following hypotheses:
Ho: Will not be able to detect pancreatic cancer significantly earlier than currently possible
HA: Will be able to detect pancreatic cancer significantly earlier than currently possible

In order to detect the cancer at an early stage, it is necessary to examine the type of
mutations undergone by genetic data which may help in predicting the potential of
developing the pancreatic cancer. A vast amount of genetic data from cases related
to different kinds of cancer can be analyzed to infer the type of mutations the genes
undergo that lead to pancreatic cancer. For this purpose, data from the National
Cancer Institute (NIH) Genomic Data Commons (GDC) is taken into consideration.
The NIH GDC portal contains information related to 22,872 genes in total, with 64
different projects which are different types of cancer. There are 3,142,246 total
number of mutations associated with these genes and projects in the NIH GDC data.
The experiment consists of data specific to all the cancer related projects. The GDC
portal also associates the impacts with every genetic mutation. One of the important
features of this experiment is the consideration of the impact caused by the genetic
mutation (For more details related to the ‘impact’ field, see Appendix D). The
machine learning classifier trained on the dataset considers the impact associated
with every mutation record. To sum up the working of the machine learning
classifier, features such as genes, and mutations along with their lethality and the
disease associated it were considered to classification model predicting whether a
subject suffers from pancreatic cancer or not. Since the features used are dependent
variables that cannot be considered as separate features, they were combined into a
single string feature. This was a binary classification model built using support
vector machine classifier. The kernel ‘Radial Basis Function’ (RBF) was used as it
2

gives better cross validation results than linear or polynomial kernels. A cross
validation with 10 splits and 3 repeats was applied on the training dataset. (Refer
Appendix E to understand more details on how the machine learning model was
built). This model produced ~85% average accuracy with a mean Receival Operator
Characteristic – Area Under Curve (ROC) of ~0.834. It showed a
decent class separability with a fairly good accuracy.
The method for evidential reasoning model was followed as discussed in this section.
The evidential reasoning model will predict the belief of developing pancreatic
cancer as well as not developing it based on the combination of propositions and
their respective masses provided as input. the ‘mass’ of a specific proposition is a
basic probability number assigned to it (Yager, Liu, Dempster, & Shafter, 2008). It
can be interpreted as the amount of belief that one has in the proposition. (See
Appendix F to learn more about the evidential model engineering). As the
propositions and their masses change, so will the prediction results. While some
combinations like high smoking history with a personal history of cancer will lead
to increase the likelihood of diagnosing pancreatic cancer, other combinations like
biopsy site away from pancreatic region with regular cell shape along with machine
learning prediction of not developing pancreatic cancer is expected to produce a
lower likelihood of pancreatic cancer development. Thus, the model will be tested
based on the computed belief value in support of pancreatic cancer for the given
scenario.
The baseline input and discount rates displayed in Table I and Table II are used to
initialize the evidential reasoning experiments. Each of the frame is assigned a
certain discount value indicating a relative importance of input features and/or
reliability of the source of the information. Initial values were selected based on a
subjective estimate of relative importance and credibility.
2

Table I
Baseline Propositions and Corresponding Support

Table II
Discount Rates and Corresponding Frames

The grouping of the baseline discount rate and initial inputs gives the following
baseline output:
Belief Of Having Pancreatic Cancer Lies Between:

(0.064, 0.142) (0)|**--------|(1)

Belief Of Not Having Pancreatic Cancer Lies Between: (0.857, 0.935) (0)|--------**|(1)
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Certain experiments are conducted by modifying the baseline propositions and the
support in them. Opinions are translated via compatibility relations and a consensus
is formed using Dempster’s rule. Dempster’s rule can be repeatedly applied to the
previous combination and combined further with an additional mass distribution if
there is any, thus forming a new consensus (Wesley & Graham, Evidence-Based
Decision Support For The Biopharmaceutical Industry, 2006). Ultimately, an
evidential interval (EI) within the belief function calculus depicting the likelihood
of developing pancreatic cancer is computed for each scenario. This is done by
conveying, translating, and combining the opinions as mentioned before. Lower
(Spt) and upper (Pls) bounds of an EI describe the degree of support attributed to the
given proposition because of the current opinions (Wesley & Graham, EvidenceBased Decision Support For The Biopharmaceutical Industry, 2006). Note that [Spt,
Pls] ⊆ [0,1]. The evidential reasoning model is tested using the following
combination of random variables to understand how each of the experiment affects
the likelihood of developing pancreatic cancer:
 Machine learning prediction, smoking history, family health history
 Machine learning prediction, and drinking history
 Machine learning prediction, biopsy location, and amount of genetic material
 Machine learning prediction, sequencing technology utilized, and quality of
sequencing read
In the experiment with combination of Machine learning prediction, smoking
history, and family health history we change the propositions and masses assigned
to these three frames and check how the increased belief in an individual with high
smoking history and a family health history of having cancer increases support in
the ML prediction of pancreatic cancer and increases the evidential interval of belief
in an individual having pancreatic cancer. In other experiment, we combine the ML
2

prediction, drinking history, and personal health history frames to determine how
the drinking history and personal health history are correlated to the ML prediction
and how their proposition values and masses assigned to them affect the evidential
interval. Further, we check how the biopsy location, and cell structure along with the
quantity of genetic material affects the evidential interval and how they support the
ML prediction as their values and masses change. Lastly, the impact on ML
prediction with changes in NGS technology and quality of sequencing reads are
tested. By changing their propositions and masses, we combine these two frames to
evaluate that the ML prediction becomes less reliable, resulting in a lower evidential
interval for pancreatic cancer as the sequencing reads become more error prone by
having a high guanine cytosine (GC) content and high homopolymer regions.
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EVALUATION OF RESULTS
The results are evaluated by training an SVC classifier and assessing its
performance. A cross validation of 10-folds repeated 3 times was applied to the SVC
classifier to measure the variance. An accuracy of 84.70% was achieved. The model
was stable with a low standard deviation of +/- 1.297%. The mean ROC AUC of
0.834, while an average precision-recall score for this classifier was 0.67. Figure 2
and Figure 3 show the area covered by the receiver operating characteristic curve
(AUC-ROC) and area covered by the precision-recall (AUC-PR) curve of the model.

Figure 2. Support Vector Classifier ROC

While Figure 2 shows an AUC-ROC of 0.834 suggesting that the model has a good
measure of separability as it is nearer to 1. Precision-Recall Curves are an intuitive
measure when evaluating imbalanced dataset like the one for this study. In Figure 3,
there is a consistent rise in precision as the recall increases. But a sharp drop in
precision at around 0.8 recall indicates that there are large numbers of fall positives
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at that point. This means that the predicted labels are incorrect when compared to
the training labels. In the imbalanced dataset, since the minority class is the positive
class, there could be a lot of negative examples that could become false positives.
Conversely, a fewer positive examples could become false negatives, hence the steep
drop in the precision.

Figure 3. Support Vector Classifier Precision-Recall

Figure 4 and Figure 5 demonstrate the confusion matrix obtained without and with
normalization. Higher proportion of true positives and true negatives suggest that
the model performs a good classification of the test data. Although the results
obtained for the machine learning classifier are promising, they still can be improved
further if the GDC data contains more pancreatic cancer related records. For the
model to avoid overfitting, there is a need to remove the imbalance present in the
data. Efforts to do this were made, but the non-pancreatic cancer records will remain
more compared to the pancreatic cancer project records which is quite obvious.
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Figure 4. Confusion matrix, without normalization
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Figure 5. Confusion matrix, with normalization

ER Experiment 1
This experiment focuses on the effect of ML prediction frame on the evidential
reasoning model.
 Baseline input
Belief Of Having Pancreatic Cancer Lies Between:
(0.063, 0.147) (0)|**--------|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.853, 0.936) (0)|--------**|(1)



The baseline input of ML prediction is changed from NOT_PC to PC with the
same mass 0.5 to see how it affects the evidential interval.
Belief Of Having Pancreatic Cancer Lies Between: (0.26, 0.374) (0)|--**------|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.626, 0.739) (0)|------**--|(1)

The results show what after changing from NOT_PC to PC, there is an increase
in the evidential interval but since the mass assigned is only 0.5, it is a small
increase.


Suppose we do not have any information about other frames but just the results
of the ML prediction. In this scenario, the mass of the ML prediction frame is set
to be 0.85 (accuracy of ML classifier) with the proposition PC without changing
the baseline beliefs in other propositions to see the effect on evidential intervals.
Belief Of Having Pancreatic Cancer Lies Between:
(0.507, 0.585) (0)|-----*----|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.415, 0.492) (0)|----*-----|(1)

Now the evidential interval of having pancreatic cancer further increases, while
the evidential interval of not having pancreatic cancer decreases as expected.
Thus, it is observed that if the belief in the ML prediction is changed from NOT_PC
to PC, while keeping the rest of inputs constant, the evidential interval of pancreatic
cancer increases and the interval for not pancreatic cancer decreases to a certain
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extent eventually both attaining almost similar values when we are considerably
confident about the ML prediction with mass 0.85.

ER Experiment 2
This experiment evaluates the effect of smoking history along with family medical
history on the likelihood of developing pancreatic cancer. Assuming that a person
does not have an active smoking history and moreover there is no family history of
cancer, it is highly unlikely that the person would develop pancreatic cancer. On the
other hand, if the smoking history is high with previous family history of cancer, the
evidential reasoning model is expected to predict more likelihood of developing
pancreatic cancer.
 Baseline input
Belief Of Having Pancreatic Cancer Lies Between:
(0.063, 0.147) (0)|**--------|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.853, 0.936) (0)|--------**|(1)



ML Prediction is set to PC with mass 0.85, smoking history set to HIGH with
mass 0.9 along with family history set to CANCER with mass 0.8 to check if the
high smoking and family history of cancer causes supports the ML prediction of
having pancreatic cancer.
Belief Of Having Pancreatic Cancer Lies Between:
(0.956, 0.974) (0)|---------*|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.026, 0.043) (0)|*---------|(1)

The evidential interval rises significantly showing that the smoking history and
family history does support the ML prediction of having pancreatic cancer as was
expected.
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Family history is set to NO_CANCER with a mass 0.9 but Smoking History is
still HIGH with mass 0.9 to check how the prediction is affected for such
scenario.
Belief Of Having Pancreatic Cancer Lies Between:
(0.686, 0.721) (0)|------**--|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.279, 0.313) (0)|--**------|(1)

Such a combination reduces the evidential interval of having pancreatic cancer
as was expected because there is no family history of cancer.


Smoking History set to MEDIUM with a mass of 0.9 and Family Medical History
set to CANCER with a mass 0.5 and ML prediction of NOT_PC with mass 0.5
to observe how setting affects prediction interval.
Belief Of Having Pancreatic Cancer Lies Between:
(0.302, 0.454) (0)|---**-----|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.545, 0.697) (0)|-----**---|(1)

The evidential interval of pancreatic cancer reduces because the ML prediction
is set to NOT_PC and even the smoking history is medium but only the family
has a medical history.


ML Prediction changed to PC with mass 0.85, Smoking History set to LOW with
a mass of 0.9 and Family Medical History set to NO_CANCER with a mass 0.9
to check if the interval for PC prediction reduces.
Belief Of Having Pancreatic Cancer Lies Between: (0.214, 0.248) (0)|--*-------|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.752, 0.785) (0)|-------*--|(1)

The interval for PC prediction reduces as expected.
From the above experiments, it is observed that as the smoking history changes from
LOW to HIGH, Family Medical History from NO_CANCER to CANCER, the
evidential interval increases rapidly. It is seen that the ML Prediction results of PC
further support increasing the interval. As the variations are made in the propositions
in Smoking History and Family Medical History, there are changes in the interval
depending also on the ML prediction mass. With HIGH Smoking History with mass
0.9 but Family History of NO CANCER with mass 0.9 the evidential interval
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becomes (0.686, 0.721) as the ML Prediction is still set to PC with mass 0.85. If the
Smoking History is reduced to MEDIUM with mass 0.9 but with Family History of
CANCER and ML prediction of NOT_PC, the interval reduces to (0.302, 0.454).
Eventually, with LOW Smoking History with mass 0.9 and NO CANCER Family
History of 0.9 along with ML prediction set to PC with mass 0.85, the interval further
reduces to (0.214, 0.248) suggesting that the propositions and their masses affect the
prediction of evidential reasoning model as expected and the ML prediction is
playing a supportive role in this.

ER Experiment 3
This experiment will try to analyze how the personal medical history, drinking
history and the ML prediction correlate with each other. If a person does not have
any history of cancer and has a low drinking history, the chances that he will develop
pancreatic cancer are low. But with the ML prediction of pancreatic cancer and a
medium to high drinking history and personal history of cancer, the expected
evidential interval of developing cancer is high.
 Baseline input
Belief Of Having Pancreatic Cancer Lies Between:
(0.063, 0.147) (0)|**--------|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.853, 0.936) (0)|--------**|(1)

 ML Prediction is set to PC with mass 0.85, to see if there is a change in the
prediction given that the drinking history set to HIGH with mass 0.8 and
Patient_Med_History set to CANCER with mass 0.9
Belief Of Having Pancreatic Cancer Lies Between:
(0.795, 0.845) (0)|-------**-|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.155, 0.204) (0)|-**-------|(1)

 The evidential increases as per expectations and thus the high medical history
and drinking history support the PC prediction.
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 Drinking history set to MEDIUM with mass 0.3 and Patient_Med_History set to
CANCER with mass 0.7 given the ML prediction of PC to see how this affects
the evidential interval.
Belief Of Having Pancreatic Cancer Lies Between:
(0.612, 0.705) (0)|------**--|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.295, 0.387) (0)|--**------|(1)

The evidential reasoning interval reduces a little as only drinking history was
changed which was expected.
 Drinking history set to HIGH with mass 0.9 and Patient_Med_History set to
NO_CANCER with mass 0.9 and PC prediction to NO_CANCER with mass 0.8
to see if the prediction is impacted.
Belief Of Having Pancreatic Cancer Lies Between: (0.202, 0.258) (0)|--*-------|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.742, 0.797) (0)|-------*--|(1)

The evidential interval for pancreatic cancer reduces as per expectations.
 ML Prediction is set to NOT_PC with mass 0.8, to see if the interval for
prediction decreases given the drinking history is set to LOW with mass 0.2 and
Patient_Med_History set to NO_CANCER with mass 0.9
Belief Of Having Pancreatic Cancer Lies Between: (0.02, 0.05) (0)|*---------|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.95, 0.979) (0)|---------*|(1)

This causes the pancreatic cancer evidential interval to reduce sharply as was
expected.
Here, different scenarios are created to evaluate the effect of drinking history and
personal medical history on the evidential intervals. With ML prediction as PC with
a mass 0.85 and Drinking History set to HIGH with mass 0.8 and Personal Medical
History set to CANCER with mass of 0.9, there is an upsurge in the evidential
interval of belief in developing pancreatic cancer from (0.063, 0.147) to (0.795,
0.845). With MEDIUM Drinking History with a mass of 0.3 the interval decreases
by a small amount to (0.612, 0.705). Finally, as the Drinking History is set to LOW
with mass 0.2 and the Medical History to NO_CANCER and ML Prediction to
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NO_PC both with masses 0.8, there is a decline in the evidential belief interval to
(0.02, 0.05), thus suggesting that the model behaves as was expected.

ER Experiment 4
In this experiment the impact of biopsy site and amount of genetic material is
observed on the ML prediction and how it affects the evidential reasoning model
prediction. It is expected that if the biopsy location is near pancreas with irregularity
in the cell result, then there might be a possibility of greater risk of cancer than if the
biopsy location is far off pancreas with regular cell result and low amount of genetic
material. With lesser amount of genetic material, it might be not enough DNA
material available to make a sensible machine learning prediction as opposed to
when the genetic material is more. For a greater likelihood of developing pancreatic
cancer, it is expected that the amount of available genetic material is high and the
cells nearing the pancreatic region are irregular.
 Baseline input
Belief Of Having Pancreatic Cancer Lies Between:
(0.063, 0.147) (0)|**--------|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.853, 0.936) (0)|--------**|(1)

 Change amount of genetic material to LARGE with a mass of 0.6 and change
biopsy site and cell result to NEAR PANCREAS and REGULAR with a mass of
0.8 and ML Prediction to PC with a mass of 0.5 to see how it affects the PC
interval.
Belief Of Having Pancreatic Cancer Lies Between:
(0.174, 0.251) (0)|-**-------|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.749, 0.825) (0)|-------**-|(1)

The evidential interval for PC decreased as per the expectations as the amount of
genetic material is large along with biopsy site near pancreas with regular the cell
structure.
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 The proposition amount of genetic material is changed from LARGE to
MEDIUM with a mass of 0.7 and change biopsy site with cell result to NOT
NEAR PANCREAS and IRREGULAR with mass of 0.9 to see if the PC
prediction is changed given ML Prediction is set to PC with a mass of 0.5
Belief Of Having Pancreatic Cancer Lies Between:
(0.37, 0.531) (0)|---***----|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.469, 0.63) (0)|----***---|(1)

The PC interval increases moderately between 0.37 and 0.53 as was expected
given the modified propositions.
 Amount of genetic material is set to SMALL with a mass of 0.8 and biopsy site
and cell result set to NEAR PANCREAS and IRREGULAR given a mass of 0.9
and ML Prediction to PC with a mass of 0.85 to see if the evidential interval for
having PC supports the input by increasing
Belief Of Having Pancreatic Cancer Lies Between:
(0.838, 0.88) (0)|--------*-|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.119, 0.162) (0)|-*--------|(1)

The evidential interval for PC prediction surges as expected.
Observation of this experiment suggest that the ML prediction of PC are not strongly
supported by a LARGE amount of genetic material as well as the results of biopsy
NEAR pancreas with REGULAR cell results. Further, with a MEDIUM quantity of
genetic material with mass 0.5 along a mass of 0.9 assigned to the biopsy site and
cell result of NOT NEAR PANCREAS and IRREGULAR and PC prediction of
mass 0.5 increases the pancreatic cancer evidential interval from (0.174, 0.251) to
(0.37, 0.531). This interval further increases as experiments are performed with
different combinations changing the propositions eventually to soar to an interval of
(0.838, 0.88) when the amount of genetic material is changed to SMALL with a mass
of 0.8, biopsy site and cell result to NEAR PANCREAS and IRREGULAR with a
mass of 0.9 and ML Prediction to PC with a mass of 0.85.

2

ER Experiment 5
Lastly, this experiment tries to observe the impact of sequence reads quality along
with the NGS technology used on the ML model. The anticipated scenario is that the
ML should become less dependable as the sequencing reads become more erroneous
meaning that they produce high guanine cytosine (GC) content and high
homopolymer regions.
 Baseline input
Belief Of Having Pancreatic Cancer Lies Between:
(0.063, 0.147) (0)|**--------|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.853, 0.936) (0)|--------**|(1)

 The proposition for sequencing reads is set to HIGH GC HIGH HMR with a mass
of 0.9 to check to see if there is a change in prediction given the ML prediction
of PC with mass 0.85.
Belief Of Having Pancreatic Cancer Lies Between:
(0.332, 0.435) (0)|---**-----|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.565, 0.667) (0)|-----**---|(1)

It is seen that the evidential interval obtained for pancreatic cancer is moderately
low suggesting error prone sequencing reads make the ML prediction unreliable
and produce lower interval which is expected.
 The mass assigned to the proposition for NGS tech is set to 0.9 to see if there is
a change in prediction given a high GC count and high homomeric region.
Belief Of Having Pancreatic Cancer Lies Between:
(0.332, 0.436) (0)|---**-----|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.564, 0.667) (0)|-----**---|(1)

There is no change in the evidence interval showing lack of impact of the NGS
tech frame.
 The proposition for NGS tech is changed from ionTorrent to ILLUMINA to
check if there is a change in the prediction given a high GC and high homomeric
region.
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Belief Of Having Pancreatic Cancer Lies Between:

(0.332, 0.436) (0)|---**-----|(1)

Belief Of Not Having Pancreatic Cancer Lies Between: (0.564, 0.667) (0)|-----**---|(1)

No change is observed in the evidential interval by changing the type of NGS
technology.


The proposition NGS tech is changed back to ionTorrent and sequencing read is
set to MOD GC LOW HMR with mass 0.9 given an ML prediction of PC with
mass 0.85 to see if the interval changes
Belief Of Having Pancreatic Cancer Lies Between:
(0.768, 0.804) (0)|-------**-|(1)
Belief Of Not Having Pancreatic Cancer Lies Between: (0.195, 0.231) (0)|-**-------|(1)

The evidential interval for PC increases considerably from (0.332, 0.436) to
(0.768, 0.804) as expected because lower quantity of GC and homomer regions
produce less faulty sequencing readings thus making the ML prediction more
reliable.
Changing the ML prediction from NO_PC to PC with a mass 0.85 increases the
evidential interval from (0.063, 0.147) to (0.507, 0.585). Further, as the sequencing
read frame is changed from LOW GC LOW HMR to HIGH GC HIGH HMR, the
evidential interval of belief in developing pancreatic cancer decreases to (0.332,
0.435). The model behaves as expected, meaning that that this change in the
sequencing model leads to the possibility of the sequencing read may lead to errors,
effectively making the ML prediction less reliable. Another observation is that
changing the NGS tech mass or its value from ION TORRENT to ILLUMINA
hardly affects the evidential interval. Even changing the sequencing read to LOW
GC HIGH HMR does not affect the interval. However, an upsurge in the evidential
interval of belief of having pancreatic cancer is observed as the NGS tech value is
change to MOD GC LOW HMR with a mass of 0.9 to (0.768, 0.804). Finally, after
changing the sequencing read to MOD GC LOW HMR with a higher belief of 0.9,
our ML prediction becomes significantly more reliable, resulting in an increase in
the evidential interval to (0.768, 0.804).
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Thus, after performing these experiments by changing the propositions and masses
assigned to them, the evidential reasoning model behaves as per expectations and
produces satisfactory results. Basic knowledge between the relationships of the input
factors is needed for verification of the behavior of the model based on the
experiment conducted.
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CONCLUSION AND DISCUSSION
The machine learning classifier used in this project is an improved version of the
previous study where the data related to all the projects in the NIH GDC portal is
considered ensuring the variability and heterogeneity of data. Although the previous
research by Sharghi reported an SVC prediction accuracy of ~91%, it was achieved
without considering the genes and mutations across to all the cancer projects which
are a part of the GDC portal. Further, the previous study did not consider the lethality
of every mutation. It was trained on a limited dataset of gene-mutation combinations
which occurred in only 185 cases of the TCGA-PAAD project.
The present study attempts to overcome these limitations by considering the
genomic data with a high ‘VEP’ impact across all the cancer projects on GDC portal.
Results achieved in this study have greater fidelity despite a lower prediction
accuracy than what Sharghi's model achieved. The model is also very stable as it has
a very low standard deviation. Thus, consideration of the most lethal and more
extensive genomic data makes this model a better version of previous research.
Further, based on given inputs, the observed results of the evidential model altered
as per the expectations. The experiments conducted presented a positive hope that
the evidential model can be used as an effective tool in the early detection of
pancreatic cancer. Factors such as accessibility to real sequencing data, accurate
family and personal history, along with more powerful and accurate NGS technology
are crucial in confirming the feasibility of this approach. An amalgamation of an
evidential reasoning approach with machine learning can prove to be a potential
solution in early diagnosis of pancreatic cancer.
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FUTURE WORK
Scope of this project included sequencing of DNA from real pancreatic tissue in the
Evidential Reasoning Model. Unfortunately, the unexpected circumstances
prevalent due to COVID-19 prevented acquiring real pancreatic cancer sequence
data from the California State University (CSU) East Bay Campus. Even though
the NIH Cancer database has protected real pancreatic cancer sequence data, present
COVID-19 circumstances has reduced their operational staff and has suspended
processing applications to obtain access to such sequence data. Thus, the future
scope of this project includes gathering the real sequencing data and incorporating it
in the developed evidential reasoning model. The source of the genomic data for this
project was The Cancer Genome Atlas Program (TCGA) which, even though being
a reliable source, has a limited database of 185 cases in the pancreatic
adenocarcinoma project. Hence, in order to improve the efficiency of the machine
learning classifier, it is desirable to seek other authentic sources to gather real
pancreatic cancer data. There is imbalance in the data currently being considered as
cases related to pancreatic cancer constitute a small proportion in the overall dataset
evaluated as opposed to non-pancreatic cancer records. Even though this project
considers sampling of the records and assigning ‘class weight’ to the model to handle
this imbalance, the model still overfits to a certain degree. Thus, the next phase of
the project should concentrate on removing the imbalance in the data. The SVC was
used as it traditionally has a good accuracy record. Future work may involve
exploring other machine learning algorithms. Moreover, to improve the evidential
reasoning model, the information related to the verified type of NGS technology
should be used to access genetic data. Along with the real sequencing data, efforts
should be made to acquire the real personal and family medical history along with
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the smoking and drinking history of individuals in order to enhance the evidential
reasoning model.
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Appendix A
PDAC originates in the ducts of pancreas, meaning that the cells present in the small
tubes which line the periphery of pancreas undergo abnormal growth, leading to
pancreatic cancer of this type. More precisely, the DNA in these cells undergo
mutations causing the anomalous proliferation of the ductal cells which is
uncontrollable. S. Amin and C. J. DiMaio describe the pathology of pancreatic
adenocarcinoma as the cancer characterized by solid and firm tumors that are highly
infiltrative (Amin & DiMaio, 2016). This study also mentions that this tumor invades
beyond the main tumor before its diagnosis and thus, the cancer spreads outside of
pancreas.
The potential causes or risk factors of pancreatic cancer are broadly classified into
‘Environmental’ and ‘Inherited’ (Gharibi, Adamian, & Kelber, 2016). Frequent
cigarette smoking and alcohol can be environmental major risk factors. Pancreatic
cancer is observed five to six times more frequently with individuals having a high
smoking history (Pandol, Apte, Wilson, Gukovskaya, & Edderkaoui, 2012).
Individuals with strong drinking history are reported to be prone to develop
pancreatic cancer with an elevated risk up to1.5 to 6-fold than the individuals with
no drinking history (Gupta, Wang, Holly, & Bracci, 2010). Diabetes mellitus and
elevated Body-Mass Index (BMI) may also be a potential cause of pancreatic cancer.
In case of inherited factors, Familial Pancreatic Cancer (FPC), a condition in which
at least two first-degree family members have pancreatic cancer may lead a person
to develop this disease. Other hereditary factors include Lynch syndrome, Peutz–
Jeghers syndrome (PJS), hereditary breast-ovarian cancer, Familial atypical multiple
mole melanoma (FAMMM), and Familial adenomatous polyposis (FAP) which
create a great probability that a person may develop pancreatic cancer having any of
these conditions inherited or in his / her family history. In addition, available options
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to treat the PDAC are radiation therapy, chemotherapy, removing the tumor by
surgery, or more than one of these techniques in combination (Gharibi, Adamian, &
Kelber, 2016).
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Appendix B
Visualization techniques such as computer tomography (CT) and magnetic
resonance imaging (MRI) are primarily used as the initial steps in pancreatic cancer
evaluation after patients start showing symptoms. These techniques are commonly
known as ultrasonography imaging of the abdomen. Some of the other visualization
methods are magnetic resonance cholangiopancreatography (MRCP), or endoscopic
ultrasound (EUS) used with CT and MRI. As per a study, EUS and fine-needle
aspiration (FNA) biopsy of the mass is mostly undergone by patients as EUS is
highly accurate while detecting small tumors of <=2 cm and focal lesions (De La
Cruz, Young, & Ruffin, 2014). EUS is specially known for detecting tumors less
than 10 mm with a sensitivity of 84% to detect 25 small tumors of 10mm coupled
with a case where EUS-FNA was used to detect masses with a size less than 10mm
in 23 patients had an accuracy of 96% (Hijioka, et al., 2017). However, detection of
cancer should be before the visualization of pancreatic masses is possible even
though visualization is a powerful aid in diagnosing pancreatic masses in order for
a longer 5-year survival rate.
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Appendix C
Sequencing is the method to determine the sequence of nucleotide bases of genome
or exome which can be performed on DNA or RNA (Gharibi, Adamian, & Kelber,
2016). Sequencing has enabled researchers to distinguish between normal and
abnormal tissues by analyzing he nucleotide bases of genomic and transcriptomic
variations, thus assisting in identification of cancerous tissues (Sharghi, 2019). NextGeneration Sequencing (NGS) is the terminology for contemporary sequencing
technologies.
As compared with digital polymerase chain reaction (PCR) method, detection of the
CTCs using NGS techniques seems to be less sensitive. Analysis of ctDNA / ctRNA
is better done with sequencing with high coverage. Sequencing data is also affected
by attributes of the NGS technique used such as read length, depth of coverage, etc.
It plays a major role in defining the accuracy and precision of the data which is to
be sequenced. A large volume of chromosome loci can be evaluated using NGS.
There are some disadvantages when using whole exome sequencing (WES).
Identifying copy number alteration (CNA) can be negatively impacted by WGS
methods. It is challenging to identify noncoding variants and rearrangements
affecting gene regulation when whole exome sequencing (WES) is used over WGS
(Wesley L. , 2019). Court et al. found out an ADO (allele drop out) rate of 85% and
the reason behind the failure of most sequencing cases to be WGA (Court, et al.,
2016).
Illumina is another powerful sequencing technology known for its highly accurate
and precise throughput (Sharghi, 2019). Even though Illumina is known to have
biases along with 1-2% error rate, it is believed to be used 90% of the times while
sequencing. Erroneous results are accountable to reasons such as crosstalk, phasing,
fading, and T accumulation, where substitution errors lead over insertion/deletion
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errors (Heydari, Miclotte, Van de Peer, & Fostier, 2019). Biases include
concentrated errors towards ends of DNA reads, whereas substitution errors happen
with incorrect detection of a base near the end of a sequence. Homopolymer errors
are commonly occur in the site of true polymorphism regions along with a case
resulting in reoccurrence of same nucleotide. It is necessary to reduce the sensitivity
of technology if these errors are to be minimized (Yeo, et al., 2012). While
comparing sequencing technologies, it was observed that Illumina sequencing
produced errors in the analysis of long polymers > 20 bases, whereas IonTorrent
sequencing methodology could not accurately predict bases in homopolymers > 8
bases nor could it read homopolymer regions > 14 bases (Quail, et al., 2012).
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Appendix D
Each mutation impacts the protein differently. As per the NIH GDC portal, every
variant impacts the mutated protein in a certain way. The nature of its impact is
observed and is distinguished based on its effect on the protein. The impact
associated with the mutation is categorized into VEP, PolyPhen, and SIFT. The
scope of this project is limited to the VEP category. The VEP impact is the effect on
the structure and the behavior of protein. It is further classified into 4 sub-categories
which are high, medium, low, and modifier. High VEP impact indicates that the
variant disrupts the protein in a way such that the protein may undergo truncation,
decay, or function loss. A moderate impact means that the variant may change the
protein effectiveness in a non-disruptive manner. On the other hand, low impact may
not change behavior of the protein and is harmless. Lastly, a modifier impact relates
to the non-coding variants, that do not leave any evidence of impact by modifying
non-coding genes.
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Appendix E
The machine learning classifier was developed to classify the mutations leading to
pancreatic cancer from other cancerous mutations. An SVC was trained on the data
from GDC portal. Different factors such as the gene, genetic mutation in that gene,
the project (or the disease) in which its occurrence is observed along with the impact
of the variant on the affected genome were considered. The data was taken for all
the genes that are available on the GDC portal which resulted into about 2.8 million
records. The records with the value ‘TCGA-PAAD’ in the project column were the
targets with value ‘1’ whereas the records with any other project were labelled as
‘0’. To obtain this data, a program was built which initially queried all the genes in
the GDC portal. For every gene, the module queried GDC data portal for all
mutations associated with the specified gene. With every mutation, the project in
which it occurred was also associated. Every mutation impacts the genome
differently, this data is also captured in the portal. Impact is categorized into ‘VEP
impact’, ‘SIFT impact’, and ‘PolyPhen impact’ and this dataset only considers
‘VEP’ impact of the genetic mutation. (See Appendix D for more details on the
impact field.) A script was developed to compute the VEP impact for each record.
Since the data size was extremely huge, there was a need to consider only the data
which was more credible to avoid consideration of data which added little value to
the set of highly impactful mutations. Hence, the dataset was sorted as per the project
the mutation was found in, based on its impact, and finally based on the genes. Out
of the sorted dataset, 5% of data from each project was considered in the final dataset
which ensured all the highly impactful records from every project were considered.
This technique ensured heterogeneity of the data and focus on the mutations with
either high, or moderate impact. In this dataset, there was an imbalance as the records
belonging to all other projects were way more than the ones belonging to pancreatic
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cancer project. The model was built by using the support vector classifier with the
‘rbf’ kernel, and the class_weight parameter equal to ‘balanced’. To measure the
variance, a cross validation of 10 folds and 3 splits was applied. Since there was a
large difference in the proportion of pancreatic cancer records and non-pancreatic
cancer records, the imbalance in the data led to overfitting of the model. To balance
the data, 2% records from every project and all the records belonging to TCGAPAAD project were considered as the final dataset and the same class classifier was
trained on it. L2 penalty or Ridge regularization was further used to evaluate the
overfitting. The data distribution of the final dataset considered is shown in the
Figure 6. The data selected was found to be normally distributed.

Figure 6. Distribution of the final dataset
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Appendix F
The evidential reasoning model consists of various input features such as ML
prediction, smoking history, medical history, drinking history, biopsy site, NGS
technology used, etc. Every input feature is considered as a frame and for every
frame has certain possibilities which are called as propositions. A frame is created
for every factor and saved in a text file called gallery_input by defining its name,
propositions, its data type such as continuous or discrete, the original frame called
as parent frame which is the source of origin of the current frame, the frame in which
the current frame will merges into called as the result frame, and lastly the
compatibility relations of the frame with other propositions. Each proposition is
assigned a certain mass which are all stored in a mass distribution file. To lessen the
impact of certainty or credibility in the belief of a frame, a discount is assigned to
every frame which is also stored in a text file. Using Dempster’s Rule, the frames
undergo fusion to form a new body of evidence which can be further used for fusing
with other bodies of evidence (Yager, Liu, Dempster, & Shafter, 2008). The final
output is computed and displayed as an interval of evidence which designates the
level of belief in the propositions which are provided as input scenarios. This is a
result of propagation of fused frames which transfuses from start to the end frame.
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